Category: Medications

Killer Caregiver?

Police arrested a nursing home nurse for killing two residents by insulin injection and the attempted murder of a third. The Pennsylvania Attorney General Michelle Henry filed charges against registered nurse Heather Pressdee. She worked at Quality Life Services in Pennsylvania. Pressdee confessed to administering lethal doses of unnecessary medication. For two of the three

Cannabis v. Opioids

The American Medical Association (AMA) published a study on medical marijuana. Cannabis provides “significant improvements” in the quality of life for people with cancer, chronic pain and insomnia. Cannabis appeared to increase wellbeing indicators. Additionally, the beneficial effects remain over time. The common conditions treated include are non-cancer chronic pain, cancer-related pain, insomnia and anxiety.

Another caregiver caught

Medication theft is a major problem in the long term care industry. Another caregiver at a long term care facility is in trouble. Aaliyah H. Patton pleaded guilty this week in Spartanburg County General Sessions Court. Law enforcement said she stole medicine prescribed to a resident at the assisted living home where she was working. Lakewood

Audit Antipsychotics

In 2012, CMS began requiring nursing homes to report antipsychotic drug use data. Some providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use. Now, CMS will audit nursing homes to determine how many residents are misdiagnosed with schizophrenia. Less than 1% of the population is

Unsafe Medications

AARP reminded us that the abuse of psychotropic medications on vulnerable residents in nursing homes are dangerous. Department of Health and Human Services’ Office of the Inspector General issued a damning report. Eight in 10 elderly nursing home residents on Medicare were prescribed psychiatric drugs. Almost a million residents per year placed at risk of unnecessary

FDA and Alzheimer’s Medications

Leqembi Leqembi is a monoclonal antibody that targets the brain’s amyloid plaques. These plaques contribute to the progression of Alzheimer’s disease. The Food and Drug Administration approved the experimental Alzheimer’s drug Leqembi (lecanemab-irmb) for clinical use in patients with early disease. It is recommended for patients in the early stages of dementia and is delivered


Contact us for a free legal consultation!